Chemomab Therapeutics collaborates with Leeds University to further elucidate the role of CCL24 in vascular damage
Chemomab’s CM-101 is a first-in-class, CCL24-neutralizing monoclonal antibody expected to enter a Phase 2 clinical trial in SSc patients early next year